Research Analysts Offer Predictions for BNGO Q1 Earnings

Bionano Genomics, Inc. (NASDAQ:BNGO) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Bionano Genomics in a research note issued to investors on Wednesday, April 9th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($3.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Bionano Genomics’ Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at ($1.87) EPS, FY2025 earnings at ($10.26) EPS, Q1 2026 earnings at ($1.60) EPS, Q2 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($5.12) EPS.

Separately, Scotiabank raised their target price on Bionano Genomics from $1.00 to $4.00 and gave the stock a “sector perform” rating in a research note on Wednesday, April 2nd.

Bionano Genomics Stock Up 2.7 %

Shares of NASDAQ BNGO opened at $4.52 on Friday. Bionano Genomics has a 1 year low of $2.68 and a 1 year high of $72.60. The company has a market capitalization of $13.59 million, a P/E ratio of -0.03 and a beta of 2.08. The company has a 50 day simple moving average of $4.10 and a 200-day simple moving average of $11.66. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99.

Institutional Investors Weigh In On Bionano Genomics

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Bionano Genomics during the 4th quarter worth approximately $118,000. Geode Capital Management LLC boosted its position in shares of Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at $46,000. XTX Topco Ltd purchased a new stake in shares of Bionano Genomics in the 4th quarter valued at $45,000. Finally, Carret Asset Management LLC lifted its stake in Bionano Genomics by 39.9% during the 4th quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock worth $34,000 after acquiring an additional 33,945 shares in the last quarter. 11.35% of the stock is currently owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.